What are Antibody Oligonucleotide Conjugates (AOCs) developed by Avidity Biosciences?

Antibody Oligonucleotide Conjugates (AOCs) are a novel class of therapies developed by Avidity Biosciences that combine the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide-based therapies.

What is the goal of Avidity Biosciences' AOC platform?

The goal of Avidity Biosciences' AOC platform is to access previously undruggable tissue and cell types and more effectively target the underlying genetic drivers of diseases.

When was Avidity Biosciences founded and where is it headquartered?

Avidity Biosciences was founded on November 13, 2012, and is headquartered in San Diego, CA.

Home / Business and Economy / Avidity Biosciences: A New Era in Gene Therapy?

Avidity Biosciences: A New Era in Gene Therapy?

27 Feb

•

Summary

Avidity Biosciences pioneers Antibody Oligonucleotide Conjugates (AOCs).
AOCs merge antibody selectivity with oligonucleotide precision.
The company aims to target previously undruggable genetic disease drivers.

Avidity Biosciences: A New Era in Gene Therapy?

Avidity Biosciences, Inc. is pioneering a groundbreaking class of therapies termed Antibody Oligonucleotide Conjugates (AOCs). This innovative platform is designed to engineer therapeutics that synergistically combine the tissue-specific targeting of monoclonal antibodies with the precise action of oligonucleotide-based treatments.

The company's unique AOC technology aims to overcome current limitations in drug development. It seeks to access previously undruggable tissue and cell types within the body.

This strategic approach allows for more effective targeting of the underlying genetic drivers responsible for various diseases. Avidity Biosciences was founded in November 2012 and is headquartered in San Diego, California. The company's core mission is to advance genetic medicine through its novel therapeutic design.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.